Ziglim 1 Tablet contains Glimepiride 1mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with insufficient endogenous insulin secretion. Ziglim 1 is typically prescribed as part of a comprehensive diabetes management plan, which includes diet, exercise, and weight control. The medication is effective in lowering both fasting and postprandial blood glucose levels. It is important to initiate therapy at the lowest effective dose to minimize the risk of hypoglycemia, a common adverse effect associated with sulfonylureas. Patients should be monitored regularly for blood glucose levels, signs of hypoglycemia, and potential allergic reactions. Caution is advised in patients with hepatic or renal impairment, and it should be used cautiously in elderly patients. Ziglim 1 is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Patient education on adherence, lifestyle modifications, and recognition of hypoglycemic symptoms is essential for optimal therapeutic outcomes. Always consult a healthcare professional before initiating or adjusting the dosage of Ziglim 1 Tablet.